Farydak
Drug Oncology
NDC 0078-0651-06
General payments
$148,035
Research payments
$74,079
Through program year 2019, $148,035 in general payments and $74,079 in research payments were reported against Farydak (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | General | $148,035 | 598 |
| 2019 | Research | $74,079 | 1 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.
The top 5 of 13 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.
The top 5 of 35 states; each share is of general payments naming this product in 2019 where a state was reported.
Records
598 general · 1 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.